Photo from wikipedia
In the LUX‐Lung 3 and LUX‐Lung 6 trials, afatinib improved overall survival in previously untreated patients with EGFR 19del mutated non‐small cell lung cancer (NSCLC) compared to chemotherapy. The appropriate… Click to show full abstract
In the LUX‐Lung 3 and LUX‐Lung 6 trials, afatinib improved overall survival in previously untreated patients with EGFR 19del mutated non‐small cell lung cancer (NSCLC) compared to chemotherapy. The appropriate management of adverse events and dose reduction of afatinib are important for EGFR‐positive NSCLC patients. We conducted a retrospective and observational study of patients treated with first‐line afatinib for EGFR‐positive NSCLC in Nagano prefecture, Japan, focusing on efficacy and toxicities.
Keywords:
non small;
afatinib;
egfr positive;
lung cancer;
cancer;
lung
Journal Title: Thoracic Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Thoracic Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!